isoxazoles has been researched along with sta 9090 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
| Pillai, RN; Ramalingam, SS | 1 |
| Agarwal, PK; Hammerich, KH; Hao, JJ; Krane, LS; Li, QQ; Neckers, L; Sanford, T; Trepel, JB; Zhang, Z | 1 |
| Brown, LE; Chatterjee, S; Collins, C; Cowen, LE; Huang, DS; Hui, R; Hutchinson, A; Krysan, DJ; LeBlanc, EV; Lindquist, S; McLellan, CA; Nation, CS; Pizarro, J; Porco, JA; Robbins, N; Shekhar-Guturja, T; Tatu, U; Trilles, R; Whitesell, L; Xie, JL | 1 |
| Eshleman, JR; Gulla, A; Kazlauskas, E; Liang, H; Matulis, D; Petrauskas, V; Strupas, K | 1 |
| Al-Lazikani, B; Antolin, AA; Clarke, PA; Collins, I; Workman, P | 1 |
2 review(s) available for isoxazoles and sta 9090
| Article | Year |
|---|---|
Hsp90 inhibitors in breast cancer: a systematic review.
Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms | 2013 |
Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Topics: Benzamides; Benzoquinones; Carcinoma, Non-Small-Cell Lung; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Resorcinols; Treatment Outcome; Triazoles | 2014 |
4 other study(ies) available for isoxazoles and sta 9090
| Article | Year |
|---|---|
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
Topics: Antineoplastic Agents; Benzamides; Benzodioxoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Histones; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Isoindoles; Isoxazoles; Protein Processing, Post-Translational; Proteomics; Resorcinols; Triazoles; Urinary Bladder Neoplasms | 2017 |
Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus.
Topics: Animals; Antifungal Agents; Candida albicans; Cell Line; Drug Resistance, Fungal; Fungal Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice; Models, Molecular; Molecular Chaperones; Protein Binding; Protein Conformation; Protein Domains; Recombinant Proteins; Resorcinols; Signal Transduction; Triazoles; Virulence | 2019 |
Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Benzamides; Benzoquinones; Carcinoma, Pancreatic Ductal; Cell Culture Techniques, Three Dimensional; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Molecular Structure; Pancreatic Neoplasms; Resorcinols; Rifabutin; Triazoles | 2021 |
Evolution of kinase polypharmacology across HSP90 drug discovery.
Topics: Binding Sites; Discoidin Domain Receptor 1; Drug Discovery; Evolution, Molecular; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Resorcinols; Triazoles | 2021 |